


## Viewpoint: do antipsychotics protect against early death? A critical view

Robert Whitaker 

Mad in America Foundation, 02139 Cambridge, MA, USA

## Invited Review

**Cite this article:** Whitaker R (2020). Viewpoint: do antipsychotics protect against early death? A critical view. *Psychological Medicine* 50, 2643–2652. <https://doi.org/10.1017/S003329172000358X>

Received: 17 June 2020  
Revised: 12 August 2020  
Accepted: 19 August 2020  
First published online: 14 October 2020

**Key words:**

Antipsychotics; mortality; schizophrenia; seriously mentally ill

**Author for correspondence:**

Robert Whitaker,  
E-mail: [rwhitaker@madinamerica.com](mailto:rwhitaker@madinamerica.com)

**Abstract**

In the past 15 years, researchers utilizing prescription databases to assess medication usage have concluded that antipsychotics reduce mortality in patients diagnosed with schizophrenia and other psychotic disorders. These findings stand in contrast to studies in non-psychiatric patients that have found that antipsychotics, because of their adverse effects on physical health, increase the risk of early death. A critical review of the evidence reveals that the worry remains. There is reason to conclude that antipsychotics contribute to the ‘mortality gap’ between the seriously mentally ill and the general population and that the database studies are plagued with methodological and reporting issues. Most importantly, the database studies tell of mortality rates within a *drug-centered* paradigm of care, which confounds any comparison of mortality risks when patients are on or off antipsychotics.

**Article**

While there has long been concern about early death among the seriously mentally ill, this worry burst into prominence in 2006 with a report by the National Association of State Mental Health Program Directors in the USA that people diagnosed with schizophrenia and other serious psychiatric disorders were dying 25 years earlier than normal. While suicide and accidental deaths account for 35%–40% of this excess mortality, nearly two-thirds is attributable to somatic diseases—cardiovascular illnesses, diabetes, and respiratory ailments in particular (Parks, Svendsen, Singer, & Foti, 2006).

The risks of developing such illnesses are known to be elevated due to the adverse effects of antipsychotics, which leads to a concern that these medications contribute to the mortality gap. However, in 2009, Finnish investigators concluded that over a 11-year period cumulative usage of antipsychotics reduced mortality (Tiihonen et al., 2009). Since then, the Finnish researchers and a handful of others have published papers that support this conclusion, which has produced headlines—at least in the USA—of this newly discovered benefit of antipsychotics.

*Science Daily*: ‘Use of antipsychotic drugs improves life expectancy for individuals with schizophrenia.’ (Johns Hopkins Medicine, 2012)

*Psychiatry and Behavior Health Learning Network*: ‘Antipsychotics appear to halve mortality risk in schizophrenia.’ (Tumolo, 2018)

This claim has come at a time that other research has led to questions about the long-term use of antipsychotics. Harrow reported that the long-term recovery rate for schizophrenia patients off antipsychotic medication was eight times higher than for medicated patients and a handful of other studies have found that the drugs may hinder long-term functioning (Albert et al., 2019; Harrow & Jobe, 2007; Wunderink, Nieboer, Wiersma, Sytema, & Nienhuis, 2013). In addition, the fact that antipsychotics appear to shrink brain volumes has led to questions about their long-term use (Murray, 2017).

The claim that antipsychotics reduce mortality rates provides a counter to those concerns (Goff et al., 2017). Thus, the question of the impact of antipsychotics on mortality rates among those diagnosed with schizophrenia becomes central to this larger question about their long-term use.

**The mortality gap**

The mortality gap between the seriously mentally ill and the general population, while it may be greater in the USA than in Finland and other Scandinavian countries, widened over the past 40 years. A systematic review of standardized mortality ratios (SMRs) of schizophrenia patients in 25 nations found that ‘all-cause mortality’ rose from 1.84 in the 1970s to 2.98 in the 1980s to 3.20 in the 1990s (Saha, Chant, & McGrath, 2007).

More recently, a UK study found that the SMR for bipolar patients, who today are often treated with second-generation antipsychotics, rose steadily from 2006 to 2014, increasing by 0.14 per year. The SMR for schizophrenia patients increased gradually from 2004 to

2010 (0.11 per year), and then more rapidly from 2010 to 2014 (0.34 per year.) (Hayes, Marston, Walters, King, & Osborn, 2017).

### The evidence that antipsychotics contribute to early death

Although it is common to categorize antipsychotics as either 'first-generation' or 'second-generation' drugs, the adverse-event profiles of individual antipsychotics vary greatly, depending on the neurotransmitter systems they disrupt and with what potency. As a class of drugs, antipsychotics may cause a long list of adverse effects, which increase the risk for a number of somatic ailments. In particular, the drugs are known to increase the risk for cardiovascular, respiratory, and endocrine diseases (Correll, Detraux, De Lepeleire, & De Hert, 2015).

#### Excess mortality among the seriously mentally ill due to somatic illnesses

Mortality studies have found varying SMRs for people diagnosed with schizophrenia (or the seriously mentally ill), both for all-cause mortality and for specific diseases (Table 1).

Two of the four studies in Table 1 charted SMRs among the seriously mentally ill in the USA (Olfson, Gerhard, Huang, Crystal, & Stroup, 2015; Parks et al., 2006) and the other two charted global SMRs (Saha et al., 2007; World Health Organization, 2015). All four found that the seriously mentally ill, a large percentage of whom are prescribed antipsychotics, die from somatic illnesses at rates two to five times that of the general population.

The excess mortality due to somatic illnesses among the seriously mentally ill is often attributed to the 'disease' or to their unhealthy behaviors, as opposed to the adverse effects of antipsychotics. Yet, even if the seriously mentally ill, quite apart from any treatment effect, often suffer from poor physical health, the adverse effects of antipsychotics could still be expected to contribute to this excess mortality.

#### Excess mortality among all users of antipsychotics

In a study published in 2013, UK investigators assessed 'mortality among antipsychotic users related to nonusers.' They utilized a database of nearly 11 million patients treated in primary care from 1995 to 2010 to identify three cohorts of patients: all users of antipsychotics, regardless of whether they had a psychiatric diagnosis; non-users from the general population; and non-users who had a psychiatric diagnosis of schizophrenia, bipolar, or depression (Murray-Thomas et al., 2013).

They reported 'fully adjusted' SMRs, meaning that sought to equalize risk factors in comparisons between any two groups, other than their use of antipsychotics. They made two important findings.

First, users of antipsychotics in the general population were almost three times as likely to die as non-users in the general population. All-cause mortality = 2.72; cardiac mortality = 1.83; sudden cardiac death = 4.03.

Second, users of antipsychotics in the general population were more likely to die than non-users with a psychiatric diagnosis. All-cause mortality = 1.75; cardiac mortality = 1.72; sudden cardiac death = 5.76.

The UK study provides evidence that antipsychotics elevate mortality in non-psychiatric patients and that non-psychiatric

**Table 1.** Excess mortality among seriously mentally ill: standardized mortality ratios

	Parks	Saha	WHO	Olfson
All-cause mortality	2.0–3.0	2.98	2.5–3.0	3.7
Cardiovascular disease	2.3	2.01	2.0–3.0	3.6
Endocrine disease	2.7	5.50	2.0–4.0	4.2
Respiratory disease	3.2	4.01	2.0–5.0	7.0 <sup>a</sup>

<sup>a</sup>SMR for pneumonia/influenza.

patients who take antipsychotics are at greater risk of dying than psychiatric patients who do not take them.

There are numerous other studies that have assessed the impact of antipsychotics on mortality rates in non-psychiatric patients, for various illnesses and in different age groups, and researchers regularly find that antipsychotics elevate SMRs for all-cause mortality and cardiac disease (Basciotta et al., 2020; Calsolaro, Antognoli, Okoye, & Monzani, 2019; Harrison et al., 2020; Hoang, Stewart, & Goldacre, 2011; Jayatilleke, Hayes, Chang, & Stewart, 2018; Jennum, Baandrup, Ibsen, & Kjellberg, 2015; Maust et al., 2015; Ralph & Espinet, 2018; Ray et al., 2019; Ray, Chung, Murray, Hall, & Stein, 2009; Weintraub et al., 2016).

In a 2018 meta-analysis, Australian investigators concluded that 'antipsychotic drugs precipitate excessive mortality across the spectrum,' including in 'general mental health care.' They wrote that all-cause mortality of 'patients prescribed antipsychotic drugs is close to two,' and is dose-related (Ralph & Espinet, 2018). (Their meta-analysis did not include studies of mortality rates in psychotic patients.)

#### Excess mortality in cohorts of psychotic patients

The studies cited above relied on large databases of medical records to calculate SMRs in patients grouped according to diagnosis or antipsychotic use. There have been a handful of studies of small cohorts of psychotic patients that have assessed whether variations in antipsychotic use affected their risk of dying.

In a study of chronic patients in Ireland, average age 62, 44% died within the next 10 years. Two-thirds died from either cardiovascular or respiratory illness. The researchers concluded that 'the greater the number of antipsychotics given concurrently, the shorter was patient survival' (Waddington, Youssef, & Kinsella, 1998).

In a 17-year study of 99 schizophrenia patients in Finland, researchers identified four groups at study entry: 20 who were not taking an antipsychotic, 31 who were taking one antipsychotic, 34 who were taking two antipsychotics, and 14 who were taking three or more. During the study, 39 of the 99 died. SMRs for the four groups, compared with the general population (matched for age and gender), were 1.29 for no-antipsychotics, 2.97 for one antipsychotic, 3.21 for two antipsychotics, and 6.83 for three or more (Joukamaa et al., 2006). The researchers concluded: 'The present study demonstrated a graded relationship between the number of neuroleptic drugs prescribed and mortality of those with schizophrenia. This relationship and the excess mortality among people with schizophrenia could not be explained by coexistent somatic diseases or other known risk factors for premature death.'

A third cohort study provides a comparison of mortality rates for first-episode psychotic patients treated either with Open Dialogue therapy in Western Lapland, Finland or conventional treatment elsewhere in the country. Open Dialogue limits both the immediate and long-term use of antipsychotics and thus this study provides a preliminary comparison between two different paradigms of care.

At the end of 19 years, only 55% of the 113 Open Dialogue group had ever been exposed to antipsychotics and only 36% were on the drugs. In contrast, 97% of the 1763 patients in the comparison group had been exposed and 81% were on antipsychotics at the end of the study. Eleven of the Open Dialogue cohort died (10%) during the lengthy follow-up, while 296 in the conventionally treated cohort died (17%). While this mortality difference was not “statistically” significant (because the number treated with Open Dialogue was so small), it is still of note that the mortality rate was lower in the group with less exposure to antipsychotics (Bergström et al., 2018).

### Suicide in the antipsychotic era

Suicide and accidents account for up to 40% of the early-death mortality among the seriously mentally ill and an even higher percentage of all deaths in the first year after diagnosis (Kasckow, Felmet, & Zisook, 2011; Parks et al., 2006). While studies have found that non-adherence to antipsychotics is associated with a higher risk of suicide, suicide rates are higher today than in the pre-antipsychotic era (before 1955), with drug side effects—and despair over their negative effects—a likely contributing cause.

### Historical rates of suicide

Although estimates of the lifetime risk of suicide in schizophrenia range from 4% to 13%, with 10% a commonly cited figure, a 2007 review of 51 studies concluded that it was around 5% (Hor & Taylor, 2010). Even that lower number is higher than the suicide rate for schizophrenia patients in the asylum era.

A study of schizophrenia patients treated at a hospital in Northern Wales from 1875 to 1924 found their lifetime suicide rate was 0.5%. This finding, the researchers concluded, is in line with ‘estimates of a lifetime rate of 1%–2% or lower reported in the methodologically strong studies in the pre-community era’ (Healy et al., 2006).

A 2002 report by SANE Australia similarly concluded that ‘the suicide rate has risen markedly since deinstitutionalization began—it is at least four times higher today than in studies from the period 1913 to 1960’ (SANE Australia, 2002).

The possible reasons for this increase are thought to be multifactorial. One thought is that asylum care was protective against suicide, and that the higher suicide rate today is a consequence of deinstitutionalization, with the seriously mentally ill poorly served by whatever community care is available. A second thought is that the arrival of antipsychotics in asylum medicine in 1955 is at least partly responsible for this increase.

An exhaustive study of suicides in US Veterans Administration hospitals provides correlative support for that second thought. From 1950 to 1954, the annual suicide rate in VA hospitals was the same for its neuropsychiatric patients as for its medical patients (around 50 per 100 000). Starting in 1955, the suicide rate for neuropsychiatric patients began to steadily climb, such that 20 years later it was eight times higher (400 per 100 000).

Although the suicide rate for medical patients went up and down during this period, it stayed well below that of the neuropsychiatric patients and in 1974 it was the same as in 1954 (50 per 100 000) (Farberow, Ganzler, & Cuttler, 1998; as cited by Healy et al., 2006). A 1962 study also found that there had been an increase in suicides after the introduction of chlorpromazine (Hussar, 1962).

There are three risk factors with antipsychotics that may impact suicide rates.

### Drug side effects

Antipsychotics induce akathisia in a significant percentage of patients, which is known to be a risk factor for suicide and violence. Second-generation antipsychotics induce akathisia—an intense inner agitation—in 15%–35% of patients (Salem, Nagpal, Pigott, & Texeira, 2017). The drugs may also induce dysphoric effects that lead to hopelessness and depression, which are risk factors for suicide (Atbaşoğlu, Schultz, & Andreasen, 2001).

A recent online survey of 832 antipsychotic users reported that 58% experienced ‘suicidality’ as a side effect of the medication, with 21% reporting it as ‘severe.’ There were a number of emotional and physical adverse effects—‘feeling not like self;’ ‘loss of motivation,’ ‘difficulty concentrating,’ ‘withdrawal effects,’ ‘emotional numbing,’ and ‘loss of sex drive’—that were strongly correlated with feelings of suicidality (Read & Williams, 2019).

Among those who thought ‘the drugs had made no difference or had made their problems worse,’ 74% said they experienced suicidality as an adverse effect of treatment. The researchers concluded: ‘Perhaps whatever degree of suicidality is generated by the adverse effects of antipsychotics, the discovery that the drugs do not work, or even make things worse, could further increase depression, hopelessness and suicidality.’

### Withdrawal as a risk factor

A significant percentage of psychotic patients treated with antipsychotics in the hospital stopped taking the drug within 12 months after discharge. In some studies, the majority do (Schoenbaum et al., 2017). A common reason for stopping is ‘medication caused unpleasant side effects.’ (Read & Williams, 2019)

This exposes them to ‘neuroleptic discontinuation syndromes,’ which is not a risk natural to the disease. Symptoms include insomnia, restlessness, nausea, mood disturbances, severe psychotic relapse, and newly emergent akathisia that may persist for long periods of time. The psychotic symptoms are often seen as a return of the disease, but users tell of a psychosis that is different in kind—and often more severe—than their pre-drug psychosis (Gardos, Cole, & Tarsy, 1978; Larsen-Barr, 2016; Larsen-Barr, Seymour, Read, & Gibson, 2018; Moncrieff, 2006; Moncrieff, Cohen, & Porter, 2013; Moser et al., 2005; Read & Williams, 2019; Tranter & Healy, 1998).

This discontinuation syndrome is known to put patients at high risk for harm. A study of schizophrenia patients who stopped filling prescriptions for olanzapine or risperidone for 30 days found that their risk of attempting suicide rose four-fold in subsequent months (Herings & Erkens, 2003).

### Therapeutic despair

First-episode psychotic patients enter into a therapeutic environment that many find profoundly depressing and isolating. They

are often told they have a chronic illness and will need to forever take a drug that they find robs them of their ability to feel and emotionally interact with the world.

In one survey, 50% of patients reported they had a ‘wholly negative’ first reaction to antipsychotics, using such words as ‘scary, terrifying, horrifying, hell, a nightmare, traumatic and disempowering’ to describe the experience (Larsen-Barr, 2016). Yet, those who refuse to take an antipsychotic will likely find themselves in conflict with family and societal demands. They find themselves in a damned-if-they-do and damned-if-they-do not situation.

After hospital discharge, this first-episode cohort breaks into two groups: those who remain medication compliant and those who stop taking antipsychotics. The suicide rate during the first year soars for the cohort as a whole, and in particular, for those who stop taking medication.

A Danish study of 9156 schizophrenia patients hospitalized for the first episode of psychosis between 1970 and 1987 found that the SMR for suicide in the first year, among those under 30 years old, was more than 200 times higher than among the general public (Mortensen & Juel, 1993).

Similarly, a US study of 5488 commercially insured first-episode psychotic patients determined that all-cause mortality in the first year was 24 times that of the general population, with nearly 2% dying during that period. More than 60% never filled a prescription for an antipsychotic in the first year following discharge (Schoenbaum et al., 2017).

Young males with good premorbid functioning—high intelligence, high level of education, good school performance, and insight into the illness ‘that leads to hopelessness’—have the highest risk of suicide (Carlborg, Winnerbäck, Jönsson, Jokinen, & Nordström, 2010). Having negative feelings about antipsychotics is also a risk factor for suicide (Sher & Kahn, 2019). These risk factors tell of higher-functioning first-episode patients who, having been exposed to antipsychotics, now view their future with despair.

### Two perspectives

The impact of antipsychotics on suicide rates for first-episode patients may be interpreted in two ways. Researchers may compare suicide rates for those who stay on their antipsychotics to those who stop taking them, and if the suicide rate is higher in the latter group, conclude that the drugs are protective against suicide. The “disease” is seen as the risk factor for suicide.

A second way is to look at the suicide rate for the entire cohort during the first year following hospitalization, which provides information about the risk of suicide *within* a drug-based paradigm of care. Treatment nonadherence—and the associated risks that entails—is understood to be an *outcome* that occurs with antipsychotic-centered care.

### The evidence that antipsychotics reduce mortality

The research most often cited as evidence that antipsychotics reduce mortality has come from a group of Finnish researchers led by Jari Tiihonen. Their studies rely on extracting information from three databases. The first is a national registry of hospitalized patients in Finland dating back to 1965, which gives a diagnosis for all patients. The second is a national database of all outpatient drug prescriptions since 1 January 1996, with each prescription linked to a specific individual by an ID number. The third is a

national death registry (Taipale et al., 2020; Tiihonen et al., 2006, 2009; Tiihonen, Mittendorfer-Rutz, Torniainen, Alexanderson, & Tanskanen, 2016; Tiihonen, Tanskanen, & Taipale, 2018).

In these studies, outpatient prescriptions serve as a proxy for medication use. If a patient living in the community fills a prescription for an antipsychotic as scheduled, then the patient is deemed to be ‘on medication’ for that time. If a patient fails to fill a prescription, then that person is deemed to be off medication for that time.

There are several methodological issues with this research that need to be understood in order to assess its merits.

### Medication usage

The outpatient prescriptions serve as a proxy for antipsychotic usage. However, since this national database did not exist before 1996, there is no assessment of antipsychotic exposure prior to that date. For instance, a person diagnosed in 1965 could have taken antipsychotics for up to 30 years and suffered adverse health effects from this usage, and yet if that person stopped taking the medication prior to 1996, he or she would be counted as a ‘non-user’ of antipsychotics in these studies. The usage of antipsychotics during hospitalization is also not known, which creates a second black hole in this research.

### Survivorship bias

In several of the Finnish studies, the average age of patients at baseline is 40 and older. As a result, the studies are assessing mortality in a cohort that has ‘survived’ treatment for a number of years, and thus may not be representative of the larger population of patients so diagnosed and treated prior to 1996. The survivors are a subgroup that apparently tolerates treatment fairly well.

### Person-year mortality rates

Tiihonen and colleagues regularly report mortality rates based on ‘person years’ of the collective time that patients spent on or off medication. In non-randomized studies, this is a method that can produce distorted results, particularly if one group can be expected to rack up many more person-years than the other.

For example, consider this scenario. A person diagnosed with schizophrenia during the first 5 years of follow-up is on an antipsychotic and alive at the end of that time. That is five ‘person-years’ of survival on an antipsychotic. Now that same person goes off the medication and dies 1-year later. That is one death in ‘one person year’ off medication. Thus, that one patient provides five ‘person years’ of survival on the drug to the total person-years equation and adds ‘one death per year’ to the off-medication total. Now imagine a second person who is on antipsychotics for 6 years and dies at the end of that 6th year. When the per-person mortality rate is tallied up for these two people, you end up with one death per 11 ‘person years’ on antipsychotics, *v.* one death per one ‘person year’ off medication.

Thus, in this calculation, the mortality rate is 11 times higher for the off-drug group, even though, during the 6 years, one person had died off medication and one had died on medication.

### Reporting outcomes as relative risks

In the Finnish studies, the ‘relative risk’ of death is regularly reported as the primary outcome (instead of the absolute number



of deaths.) However, for relative risks to be meaningful, it is necessary to compare outcomes in like populations (age, severity of illness, and so forth), and since these are not randomized studies, there may be notable differences between the ‘off med’ and ‘on med’ groups. Although Tiihonen and colleagues state, in their publications, that they have made statistical adjustments to account for inequalities in the groups being compared, they do not provide information about what the baseline inequalities are. As such, readers are left with a ‘trust us’ result (Tiihonen et al., 2009).

### *Mortality within a drug-centered paradigm of care*

The biggest problem with the database studies is that these data come from patients treated *within* a drug-centered paradigm of care. To fairly assess the impact of antipsychotics on mortality rates, it would require assessing deaths among first-episode patients treated under differing paradigms of care, one that emphasized antipsychotic usage right from the outset, and one that avoided initial use and minimized long-term use. The Open Dialogue study provided the first hint of such a comparison.

However, except in the Western Lapland region, Finnish psychiatrist regularly prescribes antipsychotics to their psychotic patients. Of the total, 97% of Finnish patients with a schizophrenia diagnosis is exposed to antipsychotics, and the usual practice is to maintain patients so diagnosed on the drugs.

Given this paradigm, those who stop taking antipsychotics after discharge from the hospital continue to suffer a multitude of drug-related risks. They may continue to suffer from cardiovascular and other health problems that arose from their exposure to the drugs. Those stopping their medication likely will suffer withdrawal symptoms—physical, emotional, and psychiatric—that increase their risk of suicide. They will likely experience the social reproach and lack of social support that those diagnosed with schizophrenia regularly experience when they stop taking antipsychotics.

Yet, with the methodology employed in the Finnish research, these mortality risks, which arise within a drug-centered paradigm of care, are chalked up as due to being ‘off medication.’ The exercise rests on a faulty premise, which is that the minute a person does not fill a prescription, the risks due to prior exposure to the drugs vanish.

With those caveats in mind, here are summaries of their three most influential reports.

### *General population studies*

(1) In a 2009 report, Tiihonen and colleagues identified 66 881 people who were admitted to a hospital with a diagnosis of schizophrenia from 1973 to 2004 and assessed their medication use, starting in 1996 based on the outpatient prescription register, for up to 11 years. They concluded that ‘long-term exposure to any antipsychotic treatment was associated with lower mortality than no drug’ (Tiihonen et al., 2009).

Their findings were summed up in a graphic that showed those who took antipsychotics for 2 years or longer were less likely to die than those who did not fill any prescriptions during the 11 years (Fig. 1).

The methodological issues discussed earlier are present in this study. There is no information about medication usage prior to 1996, even though the average age of the patients at study entry

was 51. There is no information about medication usage in the hospital, even though 64% of all deaths occurred in hospitals (De Hert, Correll, & Cohen, 2010). With a population this old, there is obvious survivorship bias. Person-years are used to calculate mortality rates. Outcomes are presented as relative risks. There is nothing about how the usage groups might have differed. All that readers can know is that the investigators sorted through the information in their three databases, performed any number of statistical adjustments, and out came a finding that told of how cumulative use of antipsychotics lowered mortality rates.

Since antipsychotics are regularly prescribed to schizophrenia patients, the first question is this: what is the makeup of the large group of patients who did not use any antipsychotics during the 11-year follow-up and yet died at high rates? There were 18 914 individuals in that no-use group, 8277 of whom died in the 11 years.

The report does not provide any descriptive information for this cohort. However, the ‘adjustments’ to the ‘crude rate ratio’ reveal that the non-users, at the start of the study, were at higher risk of dying than the other groups. This is almost certainly due to this cohort being much older than the others.

There is also a problem with the reporting of results. In their discussion, Tiihonen and colleagues state that ‘long-term use (of antipsychotics) is associated with lower mortality than is no use or short-term use.’ However, their own data reveal that this is not true.

The lowest mortality was among those who had 0–6 months of exposure to antipsychotics over an 11-year period, i.e. a group that hardly used any antipsychotic medication. Indeed, if this low-exposure group had been used as a reference for depicting relative risks, those with 7–11 years of cumulative exposure would have had a 65% greater mortality rate (Fig. 2).


With the data presented in this way, there is no clear-cut conclusion to be drawn about the impact of antipsychotics on mortality. Death rates are indeed high for those with only 6 months–2 years of exposure over the 11 years. Why might that be? At the same time, why would exposure of 0–6 months over an 11-year period produce the lowest mortality rate? Questions abound.

Given that the standard of care is to maintain schizophrenia patients on medication, here is the paradigm-challenging conclusion that Tiihonen and his colleagues could have written: ‘We found that the lowest mortality was in schizophrenia patients who, over an 11-year period, used antipsychotics for a very short time—six months or less.’


(1) In 2020, Tiihonen and colleagues provided an updated look at mortality drawn from the Finnish databases. However, rather than assess death rates based on cumulative antipsychotic usage, this study focuses on mortality related to on-off use of antipsychotics (Taipale et al., 2020).

The study examined antipsychotics usage from 1996 through 2015, based on the outpatient prescription register, for all Finnish adults diagnosed with schizophrenia and treated in a hospital between 1972 and 2014 ( $N = 62\,250$ .) The researchers found that their ‘all-cause’ risk of dying more than doubled during periods when they were not filling their antipsychotic prescriptions and that cardiovascular mortality also increased during such periods.

To understand this bottom-line result, readers must dig into the data used to calculate the relative risks of death. The average



**Fig. 1.** This is the forest plot that Tiihonen et al. (2009) used to present adjusted hazard ratios for death using ‘no antipsychotic drugs’ over 11 years as the reference group. With this reference, antipsychotic use is presented as lowering the risk of death.



**Fig. 2.** This forest plot shows the relative risk of death in Tiihonen et al. (2009) using 0-0.5 years of antipsychotic use as the reference group. When presented this way, it is evident that the group with minimal exposure to antipsychotics over 11 years had the lowest mortality rate.

age of the patients at entry into the study was 46. During a median follow-up 14.1 years, 13 899 of the 62 250 patients died (22%). There were 8264 who died while on antipsychotics and 5635 while off antipsychotics. Thus, 59% of the deaths occurred among people who were filling their prescriptions.

However, the researchers reported that the all-cause risk of dying while on medication was 0.48—less than half—that of the risk when patients were off medication. This is a conclusion made possible by the use of ‘person years’ to calculate mortality rates. Although readers need to do the math, there was one death for every 70 person years in the on-medication group (577 417 person years divided by 8264), and one death for every 33 person years in the off-medication group (187 773 person years divided by 5635.)

In their presentation of their results, Tiihonen and colleagues also published a graphic showing that antipsychotics improve survival rates at a steady pace, year after year. The graphic states that it depicts the survival rate for those who used ‘any antipsychotic *v.* those who used none.’ As such, readers could assume that there was a group in this study who never used antipsychotics for the 20 years and that 46% of these ‘non-users’ died, compared to 26% of those who used antipsychotics (Fig. 3).

Nothing like that actually happened in the study.

Here is how the graphic was created. If the mortality rate during off-antipsychotic periods was 1 in every 33 years, then, theoretically, if there were 100 patients at baseline there would be 97 alive at the end of 1 year. If you keep applying the 1-in-33 annual mortality rate for the next 19 years only 54 of the 100 would be

alive at the end of 20 years (and 46 would be dead). Apply the same person-year calculations for the ‘on-medication’ group (one death in every 70 person years), then 74 of the 100 would be alive at the end of 20 years and 26 would be dead.

The published article, however, does not describe these calculations. Moreover, there is no group identified in the study that took antipsychotics continuously for 20 years. Nor is there any group identified as never having taken antipsychotics during that period.

The graphic is best described as a statistical mirage. But it is a powerful one. You *see* the graphic and you *see* that antipsychotics steadily improved survival rates for schizophrenia patients over two decades. It is a chart that, to the eye and mind, immediately tells of drug treatment that ‘works’ over the long term.

The researchers also reported that antipsychotics reduced cardiovascular mortality, with a relative risk of 0.62 compared to non-use periods. If this study is to be believed, the very drugs that in the general population double the risk of cardiovascular mortality are protective against that risk in people diagnosed with schizophrenia.

### First-episode study

In 2006, Tiihonen and colleagues reported on deaths among 2230 adults hospitalized for a first episode of schizophrenia from 1995 through 2001, with their prescription use charted from the moment of their initial discharge (Tiihonen et al., 2006).




Fig. 3. This is the chart from Taipale et al. (2020) that presented survival rates over the 20-year study.

The average age of the first-episode patients was 30.7 years and they were followed for an average of 3.6 years. As a cohort, these patients were 'off medication' 42% of the time. In total, 75 died while in off-medication status: 26 by suicide, 25 in accidents/violence, and 24 from natural causes. Only nine died while on medication: one by suicide, four in accidents/violence, and four from natural causes.

As noted earlier, suicide rates for people diagnosed with schizophrenia increased with the introduction of antipsychotics. One possible reason is that initial use of antipsychotics in the hospital sets up a period of high risk for those who do not like the medications and stop taking them after discharge. In this study, 36% of the discharged patients did not fill a prescription within 30 days, and as can be seen, death by suicide and accident was very high for those who entered this drug-withdrawal risk pool.

The mystery data in this study is that there were six times as many deaths due to natural causes—cardiovascular mortality and such—during 'off antipsychotic' periods than in 'on antipsychotic' periods. Why would that be? This is a fairly young cohort, and so why would patients who stopped taking the drugs die so frequently from diseases that are known to be elevated by the use of the drugs?

This is a mystery worth investigating, but it would appear to be a finding that tells of how risks from antipsychotic usage, in this on-medication/off-medication binary design, get transferred to the 'off-medication' column in one way or another.

### SMRs in the database studies

Although Tiihonen did not calculate an SMR rate for the 2230 first-episode patients, a subsequent Finnish report on the 5-year outcomes of first-episode patients, which included this cohort, calculated an SMR of 4.5 (Kiviniemi, 2014). Thus, the mortality rate for first-episode patients treated within this antipsychotic-centered paradigm of care was quite high, even though Tiihonen's study attributed it to being off the drugs.

There have been a handful of other studies that utilized prescription databases to assess mortality hazards-related antipsychotic use, and their findings mostly echo the Finnish findings. They tell of lower all-cause mortality associated with regular antipsychotic use, and yet, at the same time, if they report

on SMR rates for the entire cohort, they tell of high mortality rates (Cullen et al., 2013; Khan, Faucett, Morrison, & Brown, 2013).

This finding shows up in a Swedish study that assessed outpatient prescriptions from 2006 to 2010 in a population of 21 492 patients with a schizophrenia diagnosis (Torniainen et al., 2015). The SMRs were as follows:

No exposure in 5 years: 6.3

Low exposure: 4.1

Moderate exposure: 4.0

High exposure: 5.7

Total cohort: 4.8.

This SMR of 4.8, like the SMR of 4.5 in the first-episode Finnish patients, is notably higher than the mortality ratios for schizophrenia patients in the 1970s–1990s. Saha and colleagues warned in their 2007 report that mortality rates would likely continue to rise in the era of second-generation antipsychotics because of their adverse metabolic effects, and at least in the case of these two studies, that is the case (Table 2). A 2010 review similarly concluded that 'the disparity in mortality outcomes for people with mental illness is increasing' (Lawrence, Kisely, & Pais, 2010).

There is one final SMR comparison that can be made. In the 2013 UK study, researchers reported that the adjusted SMR for schizophrenia patients who did not take antipsychotic medication was 1.9 (Murray-Thomas et al., 2013). That was less than half the SMR in the studies that are cited as providing evidence that these medications protect against early death.

### Conclusion

As can be seen in this review, there is reason to worry that antipsychotics contribute to the mortality gap among the seriously mentally ill. The adverse effects of this class of drugs—weight gain, diabetes, lipid abnormalities, and so forth—are known to increase the risk of early death.

At the same time, the evident limitations of the database studies, including the way data were presented in the published articles, undercut the conclusion that is now being told to the public, which is that research has shown that antipsychotics 'halve mortality rates.'

**Table 2.** All-cause mortality among the seriously mentally ill: 1970s to 2010

Investigator	Diagnosis	Region	Period	Standardized mortality rate
Saha	Schizophrenia	Global	1970s – 1990s	2.98
Joukamaa	Schizophrenia	Ireland	1978–1995	1 antipsychotic = 2.97 2 antipsychotics = 3.21 3 + antipsychotics = 6.83
Kiviniemi	First-episode schizophrenia	Finland	1995–2003	4.5
Olson	Schizophrenia	USA	2001–2007	3.7
Tornianen	Schizophrenia	Sweden	2006–2010	4.8

What can be concluded is that mortality rates for psychotic patients treated with the current paradigm of antipsychotic-centered care remain high, and are possibly growing worse. What is needed now are studies that compare mortality rates with different paradigms of care, one that emphasizes regular use of antipsychotics and one that minimizes their use. The Open Dialogue study was the first step toward such research.

The Finnish studies are being cited as evidence for maintaining patients diagnosed with schizophrenia on antipsychotics indefinitely. Such treatment, it is said, lowers mortality rates. But this review shows that there is reason to worry that an antipsychotic-centered *paradigm of care* is elevating mortality rates for those with psychotic disorders, and as such, provides evidence for rethinking paradigm of care.

### Acknowledgements

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

### Conflict of interest

The author is president of Mad in America Foundation, a non-profit organization that publishes a webzine on psychiatry and its treatments, Madinamerica.com. He did not receive any financial grant or support to write this article.

### References

- Albert, N., Randers, L., Allott, K., Jensen, H. D., Melau, M., Hjorthøj, C., & Nordentoft, M. (2019). Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial. *Psychological Medicine*, 49(7), 1138–1147. doi:10.1017/S0033291718001836.
- Atbaşoğlu, E. C., Schultz, S. K., & Andreasen, N. C. (2001). The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia. *Journal of Neuropsychiatry and Clinical Neurosciences*, 13(3), 336–341. doi:10.1176/jnp.13.3.336.
- Basciotta, M., Zhou, W., Ngo, L., Donnino, M., Marcantano, E. R., & Herzig, S. J. (2020). Antipsychotics and the risk of morality or cardiopulmonary arrest in hospitalized adults. *Journal of the American Geriatrics Society*, 68(3), 544–550. doi:10.1111/jgs.16246.
- Bergström, T., Seikkula, J., Alakare, B., Mäki, P., Kõngäs-Saviaro, P., Taskila, J., ... Aaltonen, J. (2018). The family-oriented open dialogue approach in the treatment of first-episode psychosis: Nineteen-year outcomes. *Psychiatry Research*, 270, 168–175. doi:10.1016/j.psychres.2018.09.039.
- Calsolaro, V., Antognoli, R., Okoye, C., & Monzani, F. (2019). The use of antipsychotic drugs for treating behavioral symptoms in Alzheimer's disease. *Frontiers in Pharmacology* Dec 6, 10, 1465. doi:10.3389/fphar.2019.01465.
- Carlborg, A., Winnerbäck, K., Jönsson, E. G., Jokinen, J., & Nordström, P. (2010). Suicide in schizophrenia. *Expert Review of Neurotherapeutics*, 10(7), 1153–1164. doi:10.1586/ern.10.82.

- Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015). Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. *World Psychiatry*, 14(2), 119–136. doi: 10.1002/wps.20204.
- Cullen, B. A., McGinty, E., Zhang, Y., dosReis, S. C., Steinwachs, D. M., Guallar, E., & Daumit, G. L. (2013). Guideline-concordant antipsychotic use and mortality in schizophrenia. *Schizophrenia Bulletin*, 39(5), 1159–1168. doi:10.1093/schbul/sbs097.
- De Hert, M., Correll, C. U., & Cohen, D. (2010). Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. *Schizophrenia Research*, 117(1), 68–74. doi:10.1016/j.schres.2009.12.029.
- Farberow, N., Ganzler, S., & Cuttler, F. (1978). *Status of suicides in veterans administrations hospitals. Reports 2–4*. Los Angeles, CA: Central Research Unit, V.A. Wadsworth Hospital Center.
- Gardos, G., Cole, J. O., & Tarsy, D. (1978). Withdrawal syndromes associated with antipsychotic drugs. *American Journal of Psychiatry*, 135(11), 1321. doi:10.1176/ajp.135.11.1321.
- Goff, D. C., Falkai, P., Fleischhacker, W. W., Girgis, R. R., Kahn, R. M., Uchida, H., ... Lieberman, J. A. (2017). The long-term effects of antipsychotic medication on clinical course in schizophrenia. *American Journal of Psychiatry*, 174(9), 840–849. doi:10.1176/appi.ajp.2017.16091016.
- Harrison, S. L., Sluggett, J. K., Lang, C., Whitehead, C., Crotty, M., Corlis, M., ... Inacio, M. C. (2020). Initiation of antipsychotics after moving to residential aged care facilities and mortality: A national cohort study. *Aging Clinical and Experimental Research* March 11. Online ahead of print. doi: 10.1007/s40520-020-01518-y.
- Harrow, M., & Jobe, T. H. (2007). Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A 15-year multifollow-up study. *Journal of Nervous and Mental Disease*, 195(5), 406–414. doi:10.1097/01.nmd.0000253783.32338.6e.
- Hayes, J., Marston, L., Walters, K., King, M. B., & Osborn, D. P. J. (2017). Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. *British Journal of Psychiatry*, 211(3), 175–181. doi:10.1192/bjp.bp.117.202606.
- Healy, D., Harris, M., Tranter, R., Gutting, P., Austin, R., Jones-Edwards, G., & Roberts, A. P. (2006). Lifetime suicide rates in treated schizophrenia: 1875–1924 and 1994–1998 cohorts compared. *British Journal of Psychiatry*, 188, 223–228. doi:10.1192/bjp.188.3.223.
- Herings, R., & Erkens, J. (2003). Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. *Pharmacoeconomics and Drug Safety*, 12(5), 423–424. doi:10.1002/pds.837.
- Hoang, U., Stewart, R., & Goldacre, M. (2011). Mortality after hospital discharge for people with schizophrenia or bipolar disorder: Retrospective study of linked English hospital episode statistics, 1999–2006. *BMJ*, 343, d5422. doi:10.1136/bmj.d5422.
- Hor, K., & Taylor, M. (2010). Suicide and schizophrenia: A systematic review of rates and risk factors. *Journal of Psychopharmacology*, 24(4 Suppl), 81–90. doi:10.1177/1359786810385490.
- Hussar, A. E. (1962). Effect of tranquilizers on medical morbidity and mortality in a mental hospital. *JAMA*, 179, 682–686. doi:10.1001/jama.1962.03050090010002.
- Jayatilake, N., Hayes, R. D., Chang, C.-K., & Stewart, R. (2018). Acute general hospital admissions in people with serious mental illness.



- Psychological Medicine*, 48(16), 2676–2683. doi:10.1017/S0033291718000284.
- Jennum, P., Baandrup, L., Ibsen, R., & Kjellberg, J. (2015). Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. *European College of Neuropsychopharmacology*, 25(11), 1906–1913. doi:10.1016/j.euroneuro.2015.08.014.
- Johns Hopkins Medicine (2012) Use of antipsychotic drugs improves life expectancy for individuals with schizophrenia. *Science Daily*. 1, November 2012. <https://www.sciencedaily.com/releases/2012/11/121101073152.htm>.
- Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. *British Journal of Psychiatry* Feb, 188, 122–127. doi:10.1192/bjp.188.2.122.
- Kasckow, J., Felmet, K., & Zisook, S. (2011). Managing suicide risk in patients with schizophrenia. *CNS Drugs*, 25(2), 129–143. doi:10.2165/11586450-000000000-00000
- Khan, A., Faucett, J., Morrison, S., & Brown, W. A. (2013). Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. *JAMA Psychiatry*, 70(10), 1091–1099. doi:10.1001/jamapsychiatry.2013.149.
- Kiviniemi, M. (2014). Mortality, disability, psychiatric treatment and medication in first-onset schizophrenia in Finland: the register linkage study. Doctoral dissertation, University of Oulu, Finland. Accessed on May 28, 2020: <http://jultika.oulu.fi/files/isbn9789526206325.pdf>.
- Larsen-Barr, M. (2016). Experiencing antipsychotic medication: from first prescriptions to attempted discontinuation. Ph.D. thesis, University of Auckland. Accessed on August 7, 2020: [https://www.researchgate.net/publication/309485009\\_Experiencing\\_Antipsychotic\\_Medication\\_From\\_First\\_Prescriptions\\_to\\_Attempted\\_Discontinuation](https://www.researchgate.net/publication/309485009_Experiencing_Antipsychotic_Medication_From_First_Prescriptions_to_Attempted_Discontinuation).
- Larsen-Barr, M., Seymour, F., Read, J., & Gibson, K. (2018). Attempting to stop antipsychotic medication: Success, supports, and efforts to cope. *Social Psychiatry and Psychiatric Epidemiology*, 53(7), 745–756. doi:10.1007/s00127-018-1518-x.
- Lawrence, D., Kisely, S., & Pais, J. (2010). The epidemiology of excess mortality in people with mental illness. *Canadian Journal of Psychiatry*, 55(12), 752–760. doi:10.1177/070674371005501202.
- Maust, D. T., Kim, H. M., Seyfried, L. S., Chiang, C., Kavanagh, J., Schneider, L. S., & Kales, H. C. (2015). Antipsychotics, other psychotropics, and the risk of death in patients with dementia, number needed to harm. *JAMA Psychiatry*, 72(5), 438–445. doi:10.1001/jamapsychiatry.2014.3018.
- Moncrieff, J. (2006). Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. *Medical Hypotheses*, 67(3), 517–523. doi:10.1016/j.mehy.2006.03.009.
- Moncrieff, J., Cohen, D., & Porter, S. (2013). The psychoactive effects of psychiatric medication: The elephant in the room. *Journal of Psychoactive Drugs*, 45(5), 409–415. doi:10.1080/02791072.2013.845328.
- Mortensen, P. B., & Juel, K. (1993). Mortality and causes of death in first admitted schizophrenic patients. *British Journal of Psychiatry*, 163, 183–189. doi:10.1192/bjp.163.2.183.
- Moser, D. J., Reese, R. L., Schultz, S. K., Benjamin, M. L., Arndt, S., Fleming, F. W., & Andreasen, N. C. (2005). Informed consent in medication-free schizophrenia research. *American Journal of Psychiatry*, 162(6), 1209–1211. doi:10.1176/appi.ajp.162.6.1209.
- Murray-Thomas, T., Jones, M. E., Patel, D., Brunner, E., Shatapathy, C. C., Motsko, S., ... Van Staa, T. P. (2013). Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: A study with the General Practice Research Database. *Cardiovascular Psychiatry and Neurology*, published online December 26, 2013:247486. doi: 10.1155/2013/247486.
- Murray, R. M. (2017). Mistakes I have made in my research career. *Schizophrenia Bulletin*, 43(2), 253–256. doi:10.1093/schbul/sbw165.
- Olsson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015). Premature mortality among adults with schizophrenia in the United States. *JAMA Psychiatry*, 72(12), 1172–1181. doi:10.1001/jamapsychiatry.2015.1737.
- Parks, J., Svendsen, D., Singer, P., & Foti, M. E. (2006). *Morbidity and mortality in people with serious mental illness*. Alexandria, VA: National Association of State Mental Health Program Directors. Retrieved from: [https://www.nasmhpd.org/sites/default/files/Mortality%20and%20Morbidity%20Final%20Report%208.18.08\\_0.pdf](https://www.nasmhpd.org/sites/default/files/Mortality%20and%20Morbidity%20Final%20Report%208.18.08_0.pdf).
- Ralph, S. J., & Espinet, A. J. (2018). Increased all-cause mortality by antipsychotic drugs: Updated review and meta-analysis in dementia and general mental health care. *Journal of Alzheimer's Disease Reports*, 2(1), 1–26. doi:10.3233/ADR-170042.
- Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. *NEJM*, 360(3), 225–235. doi:10.1056/NEJMoa0806994.
- Ray, W. A., Stein, C. M., Murray, K. T., Fuchs, D. C., Patrick, S. W., Daugherty, J., ... Cooper, W. O. (2019). Association of antipsychotic treatment with risk of unexpected death among children and youths. *JAMA Psychiatry*, 76(2), 162–171. doi:10.1001/jamapsychiatry.2018.3421.
- Read, J., & Williams, J. (2019). Positive and negative effects of antipsychotic medication: An international online survey of 832 recipients. *Current Drug Safety*, 14(3), 173–181. doi:10.2174/1574886314666190301152734
- Saha, S., Chant, D., & McGrath, J. (2007). A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? *Archives of General Psychiatry*, 64(10), 1123–1131. doi:10.1001/archpsyc.64.10.1123.
- Salem, H., Nagpal, C., Pigott, T., & Texeira, A. L. (2017). Revisiting antipsychotic-induced akathisia: Current issues and prospective challenges. *Current Neuropharmacology*, 15(5), 789–798. doi:10.2174/1570159X14666161208153644.
- SANE Australia (2002). *Schizophrenia: Costs. An analysis of the burden of schizophrenia and related suicide in Australia*. Australia: Author. Retrieved from: <https://www.madinamerica.com/wp-content/uploads/2020/04/Schizophrenia-suicideaustralia.pdf>.
- Schoenbaum, M., Sutherland, J. M., Chappel, A., Azrin, S., Goldstein, A. B., Rupp, A., & Heinssen, R. K. (2017). Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States. *Schizophrenia Bulletin*, 43(6), 1262–1272. doi:10.1093/schbul/sbx009.
- Sher, L., & Kahn, R. (2019). Suicide in schizophrenia: An educational overview. *Medicina (Kaunas)*, 55(7), 361. doi:10.3390/medicina55070361
- Taipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, J., Correll, C. U., & Tiihonen, J. (2020). 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62250 patients with schizophrenia (FIN20). *World Psychiatry*, 19(1), 61–68. doi:10.1002/wps.20699.
- Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009). 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). *Lancet (London, England)*, 374(9690), 620–627. doi:10.1016/S0140-6736(09)60742-X.
- Tiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., Alexanderson, K., & Tanskanen, A. (2016). Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. *American Journal of Psychiatry*, 173(6), 600–606. doi:10.1176/appi.ajp.2015.15050618.
- Tiihonen, J., Tanskanen, P., & Taipale, H. (2018). 20-year Nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. *American Journal of Psychiatry*, 175(8), 765–773. doi:10.1176/appi.ajp.2018.17091001.
- Tiihonen, J., Wahlbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. (2006). Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study. *BMJ*, 333(7561), 224. doi:10.1136/bmj.38881.382755.2F.
- Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Björkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015). Antipsychotic treatment and mortality in schizophrenia. *Schizophrenia Bulletin*, 41(3), 656–663. doi:10.1093/schbul/sbu164
- Tranter, R., & Healy, D. (1998). Neuroleptic discontinuation syndromes. *Journal of Psychopharmacology*, 12(4), 401–406. doi:10.1177/026988119801200412.
- Tumolo, J. (2018). Antipsychotics appear to halve mortality risk in schizophrenia. *Psychiatry & Behavioral Health Learning Network*, January 17, 2018. Published online: <https://www.psychcongress.com/article/>

- [antipsychotics-appear-halve-mortality-risk-schizophrenia.https://www.psychcongress.com/article/antipsychotics-appear-halve-mortality-risk-schizophrenia.](https://www.psychcongress.com/article/antipsychotics-appear-halve-mortality-risk-schizophrenia)
- Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. *British Journal of Psychiatry*, *173*(10), 325–329. doi:10.1192/bjp.173.4.325.
- Weintraub, D., Chiang, C., Kim, H. M., Wilkinson, J., Marras, C., Stanislawski, B., ... Kales, H. (2016). Association of antipsychotic use with mortality risk in patients with Parkinson disease. *JAMA Neurology*, *73*(5), 535–541. doi:10.1001/jamaneurol.2016.0031.
- World Health Organization (2015). *Excess mortality in persons with severe mental disorders*. Geneva, Switzerland: Author. WHO reference number: WHO/MSD/MER/16.5. Retrieved from: [https://www.who.int/mental\\_health/evidence/excess\\_mortality\\_report/en/](https://www.who.int/mental_health/evidence/excess_mortality_report/en/).
- Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. *JAMA Psychiatry*, *70*(9), 913–920. doi:10.1001/jamapsychiatry.2013.19